NCT03737643: A reported trial by AstraZeneca
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03737643 |
|---|---|
| Title | A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O). |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 4, 2019 |
| Completion date | March 28, 2025 |
| Required reporting date | March 28, 2026, midnight |
| Actual reporting date | March 13, 2026 |
| Date last checked at ClinicalTrials.gov | June 3, 2026 |
| Days late | None |